The Technical AnalystExchange: SIX Industry: Pharmaceuticals, Biotechnology & Life Sciences
Roche Holding AG Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.27% CHF220.60
America/New_York / 30 apr 2024 @ 11:31
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 179 183 mill |
| EPS: | 14.32 |
| P/E: | 15.41 |
| Earnings Date: | Jul 25, 2024 |
| SharesOutstanding: | 812.25 mill |
| Avg Daily Volume: | 1.469 mill |
| RATING 2024-04-30 |
|---|
| S |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.61x |
| Company: PE 15.41 | sector: PE 25.29 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.90x |
| Company: PE 15.41 | industry: PE 17.08 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CHF389.73 (76.67%) CHF169.13 |
| Date: 2024-05-01 |
| Expected Trading Range (DAY) |
|---|
|
CHF 216.89 - 224.31 ( +/- 1.68%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CHF220.60 (-0.27% ) |
| Volume | 1.455 mill |
| Avg. Vol. | 1.469 mill |
| % of Avg. Vol | 99.04 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ROG.SW
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ROG.SW
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.